Experimental cell therapy takes aim at Hard-to-Treat kidney cancer
Disease control
Not yet recruiting
This early study tests a new cell therapy called UCL70805F in 21 people with advanced clear cell kidney cancer that has not responded to standard treatments. The therapy uses immune cells designed to target a protein called CD70 on cancer cells. The main goals are to check safety…
Phase: PHASE1 • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC